May 14, 2013
Teva to Present at the Bank of America Merrill Lynch 2013 Health Care Conference |
| JERUSALEM--(BUSINESS WIRE)--May. 14, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV. Jon Congleton, Senior Vice President and General Manager, Global CNS will present on Wednesday, May 15, 2013.
What:
Teva Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Who:
Jon Congleton, Senior Vice President and General Manager, Read More » |
 |
May 08, 2013
Teva and Alexza Announce Teva’s License to Market ADASUVE® in the U.S. |
| Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment
of agitation associated with schizophrenia and bipolar disorder
NORTH WALES, Pa. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--May. 8, 2013-- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE (loxapine) i Read More » |
|
May 02, 2013
Teva Reports First Quarter 2013 Results |
| Click here for Webcast
Net Revenues Total $4.9 Billion
Non-GAAP Diluted EPS of $1.12; GAAP Diluted EPS of $0.74
Cash Flow from Operations of $1.1 Billion
JERUSALEM--(BUSINESS WIRE)--May. 2, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2013.
“During the quarter, we were pleased by the overall performance of our specialty products and results of our OTC joint venture. Our generic operations, which are a core component Read More » |
|
April 30, 2013
FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and Over |
| -Plan B One-Step ® Will Soon Be Available in the Family Planning Aisle in Stores Across The Country-
NORTH WALES, Pa.--(BUSINESS WIRE)--Apr. 30, 2013-- Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved the emergency contraceptive Plan B One-Step® (levonorgestrel) tablet 1.5 mg for over-the-counter sale to consumers 15 years of age and older in the United States. Th Read More » |
|
April 29, 2013
Teva Expands Management Team with Appointment of Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer |
| JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that Paul J. Sekhri has been appointed Group Executive Vice President, Global Business Development and Chief Strategy Officer. Mr. Sekhri has over 25 years of operational experience in the life sciences industry, including business development, business strategy, general management, drug development, and commercial strategy. In his new role, Mr. Sekhri will oversee Teva’s Strategy and Bus Read More » |
|
April 24, 2013
Teva Establishes Global Specialty Medicines Group |
| Move is part of strategic plan to optimize commercialization
Newly created group to utilize strong locally-led Generics presence to leverage Teva's globally-based Specialty offering
Dr. Rob Koremans appointed President and CEO of Global Specialty Medicines Group
JERUSALEM--(BUSINESS WIRE)--Apr. 24, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the creation of a Global Specialty Medicines (GSM) group. Dr. Rob Koremans will serve as President and CEO Global Specialt Read More » |
|
April 23, 2013
Teva and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402 |
| JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Apr. 23, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia (EM).
EM is a rare autosomal dominant condition characterized by debilitating spontaneous or easily evoked attacks of symmetri Read More » |
|
April 17, 2013
Teva Presented New Data from Phase III Clinical Trial of Milprosa™ (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society |
| Data Reported Comparable Multiple Pregnancy Rates Among Patients
Treated with Investigational Milprosa™ and Progesterone Vaginal Gel
JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today presented data
from a sub-analysis of a Phase III clinical trial of Milprosa™
(progesterone) vaginal ring, an investigational, once-weekly therapy for
luteal phase support in women undergoing in vitro fertilization (IVF).
Read More » |
|
April 09, 2013
Teva to Report First Quarter 2013 Financial Results on May 2, 2013 |
| JERUSALEM--(BUSINESS WIRE)--Apr. 9, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will release its first quarter 2013 financial results on Thursday, May
2, 2013 at 7:00 a.m. ET.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. ET to discuss its first quarter 2013 results and overall
business environment. A Question & Answer session will follow this
discussion.
Read More » |
|
April 08, 2013
Teva-Handok Names Yoo Suk Hong as Chief Executive Officer |
| Yoo Suk Hong, previous Lilly Korea CEO, recruited as first CEO of
Teva-Handok
Teva-Handok is scheduled to officially launch in September
JERUSALEM & SEOUL, South Korea--(BUSINESS WIRE)--Apr. 8, 2013--
Teva-Handok today announced the appointment of Yoo Suk Hong as the first
Chief Executive Officer of the business venture established between Teva
Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals
( Read More » |
|
April 08, 2013
Teva Names Ichiro Kikushige as CEO of Teva Seiyaku, Japan |
| JERUSALEM--(BUSINESS WIRE)--Apr. 8, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the
appointment of Ichiro Kikushige as Chief Executive Officer (CEO) of Teva
Seiyaku, Japan, effective on May 15, 2013. Mr. Kikushige most recently
was Senior Director of Sales for Eli Lilly Japan K.K. Mr. Kikushige will
replace Makoto Shimada, currently President and CEO of Teva Seiyaku, who
is retiring after having served the pharmaceutical indus Read More » |
|
March 29, 2013
FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy |
| -- Quartette™ Represents the Next Generation of Extended Regimen Oral
Contraceptives --
JERUSALEM--(BUSINESS WIRE)--Mar. 29, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that
the U.S. Food and Drug Administration (FDA) has approved Quartette™
(levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the
prevention of pregnancy. Quartette™ represents the next generation of
extended regimen oral contraceptiv Read More » |
|
March 21, 2013
Early versus Delayed Treatment with Laquinimod Demonstrated Significant Reduction in Risk of Disability Progression – Results of Three-Year ALLEGRO Study in Relapsing-Remitting Multiple Sclerosis |
|
Data presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) showed early treatment with laquinimod demonstrated significant benefit in terms of slowing disability progression compared to delayed treatment
36-month data affirmed the safety profile demonstrated in the ALLEGRO pivotal clinical trial
Additional animal preclinical data demonstrated laquinimod restored myelination in the brain and spinal cord
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Mar. 21, 2013 Read More » |
|
March 20, 2013
New Data Show Azilect® (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinson’s When Added to Sub-Optimally Controlled Patients on Dopamine Agonist Therapy |
| Results Add to Evidence for Azilect as an Effective and Well-Tolerated Treatment Option at Different Stages of the Progression of Parkinson’s Disease (PD)
JERUSALEM--(BUSINESS WIRE)--Mar. 20, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and H. Lundbeck A/S announced today that a double-blind, placebo controlled, randomized, multicenter study of Azilect® (rasagiline tablets) met its primary endpoint. The study, known as ANDANTE (Add oN to Dopamine AgoNists in the TrEatment of Parkins Read More » |
|
March 14, 2013
Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting |
|
LATE-BREAKING ORAL PRESENTATION PLANNED FOR AZILECT® (RASAGILINE TABLETS)
JERUSALEM--(BUSINESS WIRE)--Mar. 14, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that 15 abstracts highlighting study results for Parkinson’s disease (PD) and relapsing-remitting multiple sclerosis (RRMS) will be presented during the 65th American Academy of Neurology (AAN) annual meeting in San Diego, Calif., March 16-23, 2013. New data for AZILECT® (rasagiline tablets), an MAO-B inhibitor Read More » |
|
March 13, 2013
Clay Walker, Country Music Star And Relapsing-Remitting Multiple Sclerosis Patient Urges Others To "Stick With It" |
| Walker's Charity, Band Against MS Teams Up with Teva Pharmaceuticals to Launch Public Service Announcement Campaign and Raise Money for MS Research
FRAZER, Pa., March 13, 2013 /PRNewswire/ -- Country music singer Clay Walker today announced the launch of "Stick With It!," a national public service announcement campaign to educate relapsing-remitting multiple sclerosis (RRMS) patients about the importance of remaining adherent to a disease management routine for the long-term. Teva Pharma Read More » |
|
March 12, 2013
Teva to Present at the 2013 Barclays Global Healthcare Conference |
| JERUSALEM--(BUSINESS WIRE)--Mar. 12, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio
webcast at the 2013 Barclays Global Healthcare Conference. Eyal Desheh,
Chief Financial Officer, Teva Pharmaceutical Industries Ltd. will
present on Thursday, March 14, 2013.
Read More » |
|
March 08, 2013
Teva Files 2012 Annual Report on Form 20-F |
| JERUSALEM--(BUSINESS WIRE)--Mar. 8, 2013--
In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
announced today that it has filed its 2012 Annual Report on Form 20-F
with the U.S. Securities and Exchange Commission. The Annual Report can
be found on the company’s website at www.tevapharm.com
as well as on the SEC website at www.sec.gov.
In addition, security ho Read More » |
|
March 06, 2013
First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis |
|
CONCERTO Study Enrolling Patients Globally to Evaluate Impact of
Laquinimod on Disability Progression
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Mar. 6, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech
(NASDAQ OMX NORDIC: ACTI) announced today enrollment of the first
patient in the CONCERTO study - the third Phase III placebo-controlled
study designed to evaluate the efficacy, safety and tolerability of
once- Read More » |
|
March 04, 2013
Phase III Study of Teva’s Milprosa™ (Progesterone) Vaginal Ring Published in Fertility and Sterility |
|
Data Demonstrated Once-Weekly Milprosa™ Provides Similar Pregnancy
Rates to Daily 8 Percent Progesterone Vaginal Gel
JERUSALEM--(BUSINESS WIRE)--Mar. 4, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the
publication of results of the Phase III clinical trial of Milprosa™
(progesterone) vaginal ring in Fertility and Sterility. The study
compared the efficacy and safety of once-weekly Milprosa™ to daily 8
percent Read More » |
|
March 01, 2013
Teva Calls 5.550% Senior Notes Due 2016 for Redemption |
| JERUSALEM--(BUSINESS WIRE)--Mar. 1, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that
its finance subsidiary Teva Pharmaceutical Finance Company, LLC has
called for redemption its approximately $500 million outstanding
principal amount of 5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3).
The redemption is being funded with cash on hand.
The redemption date will be March 22, 2013, and the redemption price
w Read More » |
|
February 25, 2013
Teva to Present at the 2013 RBC Capital Markets Global Healthcare Conference |
| JERUSALEM--(BUSINESS WIRE)--Feb. 25, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio
webcast at the 2013 RBC Capital Markets Global Healthcare Conference.
Jon Congleton, SVP, Global Medicines Group, will present on Wednesday,
February 27, 2013.
What:
Teva Presentation at the 2013 RBC Capital Markets Global He Read More » |
|
February 22, 2013
Additional QNASL® (beclomethasone dipropionate) Nasal Aerosol Data to be Presented at Annual Allergy Meeting |
| Data to be Presented Regarding Impact on Sleep Quality and Nasal Symptom Relief at 24 Hours Post Dose in Patients with Seasonal and Perennial Allergic Rhinitis
JERUSALEM--(BUSINESS WIRE)--Feb. 22, 2013-- Teva Pharmaceutical Industries Ltd. announced today that additional data analyzed from the Phase III clinical program for QNASL® (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Ant Read More » |
|
February 14, 2013
Teva Announces FDA Approval of Generic Adderall XR® |
| JERUSALEM--(BUSINESS WIRE)--Feb. 14, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that
the U.S. Food and Drug Administration (FDA) has approved its Abbreviated
New Drug Application (ANDA) for the generic version of Shire’s Adderall
XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg and 30 mg capsules for the
treatment of attention deficit hyperactivity disorder. Adderall XR® had
annual sales, including brand and generic sales, of ap Read More » |
|
February 11, 2013
Teva Pharmaceuticals Announces Appointment of Dr. Arie Belldegrun to Board of Directors |
| JERUSALEM--(BUSINESS WIRE)--Feb. 11, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that
Dr. Arie Belldegrun was appointed by the Board of Directors of Teva, at
its meeting of February 5, 2013, to fill a vacancy on the Board
effective immediately. Dr. Belldegrun's term of office will extend until
Teva’s 2013 Annual Meeting of Shareholders.
“We are pleased to welcome Dr. Belldegrun to our Board. Arie’s extensive
Read More » |
|
February 07, 2013
Teva Reports Fourth Quarter and Full Year 2012 Results |
| Click here for Webcast
Fourth Quarter 2012 Net Revenues of $5.2 Billion and Full Year Net Revenues of $20.3 Billion
Fourth Quarter 2012 Non-GAAP Diluted EPS of $1.32, GAAP Diluted EPS of $0.37; Full Year Non-GAAP Diluted EPS of $5.35, GAAP Diluted EPS of $2.25
15% Increase in Quarterly Dividend
Share Repurchases of $0.5 Billion and $1.2 Billion in Fourth Quarter and Full Year 2012, Respectively
Cash Flow from Operations of $1.6 Billion and $4.6 Billion in Fourth Quarter and Full Year Read More » |
|
February 05, 2013
Teva Announces First Patient Enrolled in Largest Clinical Study to Date Evaluating AZILECT® for Mild Cognitive Impairment in Parkinson's Disease |
| JERUSALEM--(BUSINESS WIRE)--Feb. 5, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today
enrollment of the first patient in the MODERATO study – a Phase IV
clinical study designed to evaluate the effect of AZILECT®
(rasagiline tablets) on cognitive function in adults with mild cognitive
impairment (MCI) in Parkinson's disease (PD-MCI).
“Cognitive impairment in PD is a major cause of disability and increased
care part Read More » |
|
January 31, 2013
Teva Announces Termination of Agreements with CureTech |
| JERUSALEM--(BUSINESS WIRE)--Jan. 31, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the
termination of its collaboration with CureTech Ltd.
"We are in the process of conducting a disciplined review of our
pipeline. As we looked closely at CT-011 and the most recent clinical
and biochemical data, we have made the strategic decision to invest our
resources elsewhere where we can have the most impact for patients,”
Read More » |
|
January 23, 2013
Teva Reports Top-Line Results from Second Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated with Bipolar 1 Disorder |
|
-Following first, positive trial, second trial fails to demonstrate
efficacy in meeting primary and secondary endpoints
-Teva remains committed to clinical development program with third,
ongoing phase III and open-label extension trials
JERUSALEM--(BUSINESS WIRE)--Jan. 23, 2013--
Teva Pharmaceutical Industries Ltd. today announced top-line results of
its Phase III clinical program for armodafinil (NUVIGIL®) as
adjunct therapy Read More » |
|
January 22, 2013
Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013 |
| JERUSALEM--(BUSINESS WIRE)--Jan. 22, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will release its fourth quarter and full year 2012 financial results on
Thursday, February 7, 2013 at 7:00 a.m. EST.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. EST to discuss its fourth quarter and full year 2012 results
and overall business environment. A Question & Answer session will
Read More » |
|
January 07, 2013
Teva to Present at the 31st Annual J.P. Morgan Healthcare Conference |
| JERUSALEM--(BUSINESS WIRE)--Jan. 7, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio
webcast at the J.P. Morgan Healthcare Conference in San Francisco, CA.
Dr. Jeremy Levin, President & CEO, Teva Pharmaceutical Industries Ltd.,
will present on Tuesday, January 8, 2013.
Read More » |
|
